Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to alleged false and misleading statements regarding its financial reporting and internal controls during the class period from October 7, 2020, to March 19, 2024 [1][5]. Group 1: Class Action Details - The Rosen Law Firm is reminding investors who purchased Lifecore securities during the class period of the September 27, 2024, deadline to become a lead plaintiff in the class action [1][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. Group 2: Allegations Against Lifecore - The lawsuit claims that Lifecore had deficient internal controls over financial reporting, leading to inaccurate financial statements that required restatement [5]. - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing its ability to file periodic reports with the SEC in compliance with NASDAQ requirements [5]. - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated, resulting in misleading public statements [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, enhancing the firm's credibility in handling such cases [4].

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

Charleston, South Carolina, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Poulin Willey Anastopoulo LLC announces that a class action has been filed in the United States District Court for the District of Minnesota on behalf of all persons and entities that purchased or otherwise acquired (or owned) the securities of Lifecore Biomedical, Inc. ("LFCR" or the "Company") (NASDAQ:LFCR) between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"). The Company, together with its subsidiaries, operat ...

Core Viewpoint - A class action lawsuit has been filed against Lifecore Biomedical, Inc. for alleged deficiencies in financial reporting and internal controls, impacting the company's share price and financial statements [1][2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Lifecore securities from October 7, 2020, to March 19, 2024, with a deadline of September 27, 2024, for lead plaintiff applications [1]. - Allegations include Lifecore maintaining deficient internal controls, resulting in inaccurate financial statements that require restatement [3]. - The company’s remediation efforts regarding these deficiencies were deemed ineffective, impairing its ability to file timely reports with the SEC [3]. Group 2: Financial Impact - Between September 2022 and February 2024, Lifecore's share price declined due to disclosures about material weaknesses in internal controls and delays in SEC filings [2]. - The lawsuit claims that Lifecore's financial position and prospects were materially overstated as a result of these issues [3].

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/LFCR. NEW YORK, ...

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR). If you incurred significant losses and want to act as the lead plaintiff in the Lifecore class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW CLASS PERIOD: Oct ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore ...